Conjugated Via A Specifically-identified Linking Group, Chelating Group, Coordination Complex, Coupling Agent, Or Conjugation Agent Patents (Class 530/391.5)
  • Patent number: 10143653
    Abstract: A multi-component nanochain for use in diagnostic and therapeutic applications includes at least three nanoparticles linked together to form the nanochain. At least one nanoparticle of the nanochain has an asymmetric surface chemistry defined by asymmetrically disposed first linkers and second linkers. The nanoparticles are linked to form the nanochain by linking first linkers and/or second linkers disposed on separate nanoparticles.
    Type: Grant
    Filed: September 12, 2016
    Date of Patent: December 4, 2018
    Assignee: Case Western Reserve University
    Inventors: Efstathios Karathanasis, Watuthantrige Pubudu M Peiris, Mark Griswold
  • Patent number: 10046086
    Abstract: A biodegradable scaffold, a low-molecular weight thioketal, and a method of forming a biodegradable scaffold are provided. The biodegradable scaffold includes a thioketal and an isocyanate, where the thioketal is linked to the isocyanate to form the scaffold. The low-molecular weight thioketal includes 2,2-dimethoxypropane and thioglycolic acid, wherein the thioketal includes at least two hydroxyl terminal groups. The method of forming the biodegradable scaffold includes blending a thioketal with an excess isocyanate, forming a quasi-prepolymer, mixing the thioketal, the quasi-prepolymer, and a ceramic, and then adding a catalyst to form the biodegradable scaffold. The thioketal is a low-molecular weight thioketal having at least two hydroxyl terminal groups.
    Type: Grant
    Filed: October 11, 2016
    Date of Patent: August 14, 2018
    Assignee: Vanderbilt University
    Inventors: Scott A. Guelcher, Madison McGough, Mukesh K. Gupta, Craig L. Duvall, John Martin, Jon Page
  • Patent number: 9403875
    Abstract: Disclosed is a class of versatile Sarcophagine based bifunctional chelators (BFCs) containing a hexa-aza cage for labeling with metals having either imaging, therapeutic or contrast applications radiolabeling and one or more linkers (A) and (B). The compounds have the general formula where A is a functional group selected from group consisting of an amine, a carboxylic acid, an ester, a carbonyl, a thiol, an azide and an alkene, and B is a functional group selected from the group consisting of hydrogen, an amine, a carboxylic acid, and ester, a carbonyl, a thiol, an azide and an alkene. Also disclosed are conjugate of the BFC and a targeting moiety, which may be a peptide or antibody. Also disclosed are metal complexes of the BFC/targeting moiety conjugates that are useful as radiopharmaceuticals, imaging agents or contrast agents.
    Type: Grant
    Filed: January 27, 2010
    Date of Patent: August 2, 2016
    Assignee: UNIVERSITY OF SOUTHERN CALIFORNIA
    Inventors: Peter S. Conti, Hancheng Cai, Zibo Li, Shuanglong Liu
  • Patent number: 9347946
    Abstract: The present invention provides reagents containing binding moieties conjugated to dextran moieties, methods of making such reagents, and use of such reagents in a variety of molecular and cellular assays.
    Type: Grant
    Filed: September 22, 2011
    Date of Patent: May 24, 2016
    Assignee: BIOCEPT, INC.
    Inventors: Stephen D. Mikolajczyk, Lisa S. Millar
  • Patent number: 9140706
    Abstract: The present disclosure is directed to a reactive ester agent capable of conjugating a reporter molecule to a carrier molecule or solid support. The reactive ester agent has the general formula: wherein the variables are described throughout the application.
    Type: Grant
    Filed: August 21, 2013
    Date of Patent: September 22, 2015
    Assignee: Life Technologies Corporation
    Inventors: Evan Antoulinakis, Kyle Gee, Aleksey Rukavishnikov
  • Publication number: 20150125878
    Abstract: The invention provides an antibody or fragment thereof that specifically binds to human endothelial vascular cell adhesion molecule-1 (VCAM-1), wherein the antibody or fragment thereof binds to the extracellular domain of VCAM-1, and wherein the antibody or fragment thereof binds to VCAM-1 when expressed on endothelial cells, wherein the antibody or fragment thereof is a human or humanized antibody, or fragment thereof.
    Type: Application
    Filed: April 24, 2013
    Publication date: May 7, 2015
    Inventors: Daniel Clive Anthony, Sandra Jane Campbell, Francis Joseph Carr, Robin Patrick Choudhury, Benjamin Guy Davis, Timothy David Jones, Nicola Ruth Sibson
  • Publication number: 20150125473
    Abstract: The present invention concerns a process for the preparation of an antibody conjugate comprising the step of reacting an engineered antibody having a single inter-heavy chain disulfide bond with a conjugating reagent that forms a bridge between the two cysteine residues derived from the disulfide bond.
    Type: Application
    Filed: June 19, 2013
    Publication date: May 7, 2015
    Inventors: John Burt, Antony Godwin, George Badescu
  • Publication number: 20150119553
    Abstract: Compounds are disclosed that are useful for noninvasive imaging in the near-infrared spectral range.
    Type: Application
    Filed: November 24, 2014
    Publication date: April 30, 2015
    Inventors: Xinshe Xu, Daniel R. Draney, Lael Cheung
  • Publication number: 20150119281
    Abstract: A phosphine derivative of DyLight dyes modified with ethylene glycol or (poly)ethylene glycol groups. In one embodiment, the compounds are useful in chemoselective ligation reactions.
    Type: Application
    Filed: October 29, 2014
    Publication date: April 30, 2015
    Applicants: Pierce Biotechnology, Inc., Dyomics GmbH
    Inventors: Greg Hermanson, Peter T. Czerney, Surbhi Desai, Suk J. Hong, Matthias S. Wenzel, Boguslawa R. Dworecki, Frank G. Lehmann
  • Publication number: 20150110817
    Abstract: A tissue-targeting complex comprising a tissue targeting moiety, an octadentate hydroxypyridinone-containing ligand comprising four HOPO moieties and the ion of an alpha-emitting thorium radionuclide, where at least one of the four HOPO moieties is substituted at the N-position with a hydroxyalkyl solubilising group.
    Type: Application
    Filed: May 13, 2013
    Publication date: April 23, 2015
    Inventors: Hanne Therese Bonge-Hansen, Olav Benjamin Ryan
  • Publication number: 20150104385
    Abstract: A tissue-targeting complex comprising a tissue targeting moiety, an octadentate hydroxypyridinone-containing ligand comprising four HOPO moieties and the ion of an alpha-emitting thorium radionuclide, where at least one of the four HOPO moieties is substituted at the N-position with a hydroxyalkyl solubilising group and wherein the tissue targeting moiety has binding affinity for the CD22 receptor. Methods of treatment utilising such complexes and methods of formation of such complexes are provided.
    Type: Application
    Filed: May 13, 2013
    Publication date: April 16, 2015
    Applicant: Algeta ASA
    Inventors: Hanne Therese Bonge-Hansen, Olav Benjamin Ryan
  • Publication number: 20150104468
    Abstract: The present disclosure provides methods of site-specific labeling of antibodies, using proteins having 4?-phosphopantetheinyl transferase activity that catalyze post-translational modification of peptide sequences (“peptide tags”) incorporated into one or more specific sites of an antibody of interest. Enzymatic labeling enables quantitative and irreversible covalent modification of a specific serine residue within the peptide tags incorporated into the antibody, and thus creates desirable antibody conjugates.
    Type: Application
    Filed: May 31, 2013
    Publication date: April 16, 2015
    Applicant: IRM LLC
    Inventors: Bernhard Hubert Geierstanger, Jan Grunewald, Badry Bursulaya
  • Publication number: 20150086576
    Abstract: In some aspects, polypeptides comprising single domain antibodies and methods of identifying single domain antibodies are provided. In some embodiments polypeptides comprising a single domain antibody and a sortase recognition sequence, are provided. In some aspects, products and methods of use in modulating the immune system, e.g., modulating an immune response, are provided.
    Type: Application
    Filed: April 15, 2013
    Publication date: March 26, 2015
    Inventors: Hidde Ploegh, Maximilian Popp, Juanjo Cragnolini
  • Patent number: 8980265
    Abstract: Subject matter of the invention are antibody-cytokine fusion proteins having proapoptotic and immune modulating properties, but wherein the cytokine moiety a priori has a bioactivity which is very low or restricted to certain receptor subtypes. These reagent exert their full biological activity via the corresponding cytokine receptor(s) only after antibody-mediated binding of the fusion protein to a specific cell membrane-expressed target molecule. By suitable choice of the antibody specificity, the cytokine activity is directed to the tissue, e.g. tumor tissue, to be treated, and a therapeutic agent can be produced being specifically designed/optimized for the respective indication/tumor entity.
    Type: Grant
    Filed: March 14, 2003
    Date of Patent: March 17, 2015
    Assignee: BioNTech AG
    Inventors: Klaus Pfizenmaier, Harald Wajant, Dieter Moosmayer, Thomas Wuest
  • Publication number: 20150072396
    Abstract: Low-copper click chemistry, 1.3-dipolar cycloadditions, and Staudinger ligations for modifying biomolecules is provided. Compositions, methods, and kits relating to low-copper click chemistry, 1.3-dipolar cycloadditions, and Staudinger ligations are also provided.
    Type: Application
    Filed: March 1, 2012
    Publication date: March 12, 2015
    Applicant: LIFE TECHNOLOGIES CORPORATION
    Inventors: Kyle Gee, Upinder Singh, Scott Grecian, Scott Clarke
  • Publication number: 20150038672
    Abstract: Targeting agents are derived from coupling together formed imaging amino acids or formed multi-modal, multi-chelating metal, multi-dye imaging agents, or combinations of these, that may be conjugated directly, or activated, or attached to linkers to which targeting groups, such as peptides, proteins, antibodies, aptamers, or small molecule inhibitors, may be conjugated in the final steps of the synthesis to form a wide variety of TMIAs.
    Type: Application
    Filed: August 1, 2014
    Publication date: February 5, 2015
    Applicant: Rochester Institute of Technology
    Inventors: Hans F. Schmitthenner, Stephanie Beach, Chelsea Weidman, Taylor Barrett
  • Patent number: 8946393
    Abstract: A method for diagnosing Lyme disease status in a mammal is provided. The method entails, in a biological sample obtained or derived from a mammal, determining antibodies to Borrelia burgdorferi (B. burgdorferi) outer surface proteins (Osp) OspA, OspC, and OspF. Based upon determining the OspA, OspC, and OspF antibodies, the mammal can be diagnosed as vaccinated, not vaccinated, infected or not infected with B. burgdorferi. Mammals that have early, intermediate or chronic B. burgdorferi infection can also be identified. The method is particularly suited for use with horses and dogs. Isolated or recombinant B. burgdorferi antigens and compositions that contain them are also provided.
    Type: Grant
    Filed: September 27, 2011
    Date of Patent: February 3, 2015
    Assignee: Cornell University
    Inventor: Bettina Wagner
  • Publication number: 20150031046
    Abstract: A bioanalytical reagent used in a heterogeneous phase and a usage method thereof are provided to increase the signal intensity from the bioanalytical reagent. The bioanalytical reagent includes a target detector and a signal generator. The signal generator is represented by the following formula: (p1) y-(a trigger)z-(LS) N-a degradable polymer coupled with a contrast agent in latent state via covalent bonds-p2, wherein p1 is a protecting group for the end group of the trigger, LS is a self-immolative linker or spacer, p2 is a protecting group for the end group of the degradable polymer, y is 0 or 1, and Z, N are non-negative integer. The signal generator is in a latent state during wash and separation procedures, until an inducing matter or a condition, which excites the contrast agent from a latent state to an active state, is added or applied into the analysis system after the separation procedure so as to degrade directly the polymer or to stimulate the triggers in sequence before degrading the polymer.
    Type: Application
    Filed: May 24, 2011
    Publication date: January 29, 2015
    Inventor: Lijun Dai
  • Publication number: 20150024458
    Abstract: Disclosed herein are methods and compositions dock and lock (DNL) complexes comprising an AD moiety selected from an AKAP protein and a DDD moiety selected from a protein kinase A regulatory subunit. Also disclosed are fusion proteins comprising an AD moiety or DDD moiety attached to an effector moiety. The DDD moieties form dimers that bind to the AD moiety to form the DNL complexes. The effector moieties may be selected from a wide range of known effector moieties that produce one or more physiological effects, including but not limited to cell death. The DNL complexes may further comprise one or more diagnostic and/or therapeutic agents. The DNL complexes are of use for treating and/or diagnosing a variety of diseases or conditions.
    Type: Application
    Filed: October 1, 2014
    Publication date: January 22, 2015
    Inventors: Chien-Hsing Chang, David M. Goldenberg
  • Publication number: 20150017094
    Abstract: Antibodies are engineered by replacing one or more amino acids of a parent antibody with non cross-linked, highly reactive cysteine amino acids. Antibody fragments may also be engineered with one or more cysteine amino acids to form cysteine engineered antibody fragments (ThioFab). Methods of design, preparation, screening, and selection of the cysteine engineered antibodies are provided. Cysteine engineered antibodies (Ab) are conjugated with one or more zirconium complex (Z) labels through a linker (L) to form cysteine engineered zirconium-labeled antibody conjugates having Formula I: Ab-(L-Z)p??I where p is 1 to 4. Imaging methods and diagnostic uses for zirconium-radiolabeled, cysteine engineered antibody conjugate compositions are disclosed.
    Type: Application
    Filed: June 10, 2014
    Publication date: January 15, 2015
    Inventors: Herman Gill, Jagath R. Junutula, Henry B. Lowman, Jan Marik, Jeff Tinianow, Simon Williams
  • Publication number: 20150018523
    Abstract: This invention provides compositions and methods for producing translational components that expand the number of genetically encoded amino acids in eukaryotic cells. The components include orthogonal tRNAs, orthogonal aminoacyl-tRNA synthetases, orthogonal pairs of tRNAs/synthetases and unnatural amino acids. Proteins and methods of producing proteins with unnatural amino acids in eukaryotic cells are also provided.
    Type: Application
    Filed: July 22, 2014
    Publication date: January 15, 2015
    Inventors: Alexander Deiters, T. Ashton Cropp, Jason W. Chin, J. Christopher Anderson, Peter G. Schultz
  • Patent number: 8927695
    Abstract: Embodiments of the invention are related to a polypeptide comprising the amino acid sequence of a human IgE-Fc C?3-C?4, wherein said C?3-C?4 starts at amino acid 328 and ends at amino acid 547 of said IgE-Fc, and wherein C 328 is A and K 367 is C. Other embodiments concern a second polypeptide comprising the amino acid sequence of a human Fc?RI? extracellular region, wherein said extracellular region starts at amino acid 1 and ends at amino acid 176 of said Fc?RI?. Still other embodiments are related to a method of identifying a compound that inhibits the binding of an IgE-Fc to a Fc?RI?, said method comprising: contacting the polypeptide, wherein said IgE-Fc C?3-C?4 sequence is labeled with a fluorophore, and the second polypeptide, with a test compound; and determining whether binding of said polypeptide to said second polypeptide is decreased in the presence of said test compound.
    Type: Grant
    Filed: March 29, 2011
    Date of Patent: January 6, 2015
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Theodore S Jardetzky, Beomkyu Kim
  • Publication number: 20150005477
    Abstract: The invention relates generally to compositions and methods for conjugating antibodies and activatable antibodies, and methods of partially reducing antibodies and/or activatable antibodies prior to conjugation, e.g., thiol-based conjugation, with an agent, e.g., a therapeutic and/or diagnostic agent.
    Type: Application
    Filed: June 4, 2014
    Publication date: January 1, 2015
    Inventors: Henry Bernard Lowman, Luc Roland Desnoyers, Tony W. Liang, Andrei William Konradi, Shweta Singh
  • Patent number: 8916504
    Abstract: The present invention features improved methods of in vitro RNA display to allow reliable expression and selection of scFv antibody molecules from expression libraries. The improved methods, in part, involve the use of mildly reducing conditions, which favor of scFv intra-chain disulphide bond and thus correct folding of the scFv antibody molecules. Although particularly suited to expression and selection of scFv antibody molecules, the methods of the invention are also expedient for in vitro RNA display of all classes of protein.
    Type: Grant
    Filed: September 30, 2009
    Date of Patent: December 23, 2014
    Assignee: Abbvie Inc.
    Inventors: Chung-Ming Hsieh, Yuliya A. Kutskova, John E. Memmott
  • Publication number: 20140350227
    Abstract: The present invention relates to a novel coumarin derivative, to a method for preparing the same, and a multi-fluorescent substance that includes a plurality of the coumarin derivatives and is able to emit light using an LED light source. A novel coumarin derivative multi-fluorescent substance according to the present invention has an optimal emission wavelength band of 512 nm to 590 nm and thereby is effective in improving a signal intensity and stability since light emission using an LED light source is possible. In addition, higher fluorescence reactivity is exhibited compared to coumarin fluorescent substances known in the related arts since one molecule has a plurality of fluorescent substances, and the problem of the coumarin fluorescent substance possibly binding to a binding site of the antigen of the antibody is solved since fluorescence detection is possible even when a minimum number of fluorescent substance molecules bind to an antibody.
    Type: Application
    Filed: March 5, 2012
    Publication date: November 27, 2014
    Applicants: ACCOBIOTECH SDN BHD., GENBODY INC.
    Inventors: Hyun Park, Hak Sung Kim, Hyun Ok Song, Chom Kyu Chong, Sung Yeon Kim
  • Patent number: 8883162
    Abstract: The present invention concerns methods and compositions comprising an anti-IGF-1R antibody or fragment thereof for treatment of cancer or autoimmune disease. Preferably, the cancer is renal cell carcinoma, breast cancer or pancreatic cancer. The anti-IGF-1R antibody or fragment may be part of a complex, such as a DOCK-AND-LOCK™ (DNL™) complex. Preferably, the DNL™ complex also comprises a second antibody, a second antibody fragment, an affibody or a cytokine. More preferably, the cytokine is interferon-?2b. Most preferably, the second antibody, second fragment or affibody binds to IGF-1R, TROP2 or CEACAM6. The anti-IGF-1R antibody or complex may be administered alone or in combination with a therapeutic agent, such as an mTOR inhibitor.
    Type: Grant
    Filed: November 29, 2012
    Date of Patent: November 11, 2014
    Assignee: IBC Pharmaceuticals, Inc.
    Inventors: Chien-Hsing Chang, David M. Goldenberg
  • Patent number: 8865122
    Abstract: A modular platform is provided for rapid preparation of various water-soluble prosthetic groups capable to efficiently introduce 18F into proteins with 18F labelling reagents.
    Type: Grant
    Filed: April 2, 2013
    Date of Patent: October 21, 2014
    Assignee: Genentech, Inc.
    Inventors: Herman Gill, Jan Marik, Jeff Tinianow, Simon Williams
  • Patent number: 8865875
    Abstract: The present invention provides antibodies (e.g., IgG antibodies) having C-terminal cysteine-containing extensions that facilitate antibody conjugation to a partner molecule (e.g. a drug, toxin, marker molecule, protein, radioisotope, or other therapeutic agent). Methods of making, screening and selecting the antibodies of the invention are provided.
    Type: Grant
    Filed: August 19, 2008
    Date of Patent: October 21, 2014
    Assignee: Medarex, L.L.C.
    Inventors: Jie Liu, David King
  • Publication number: 20140308302
    Abstract: Anti-5T4 antibodies, anti-5T4 antibody/drug conjugates, and methods for preparing and using the same.
    Type: Application
    Filed: May 29, 2014
    Publication date: October 16, 2014
    Inventors: Erwin R. BOGHAERT, Nitin K. DAMLE, Philip Ross HAMANN, Kiran KHANDKE, Arthur KUNZ, Kimberly A. MARQUETTE, Lioudmila TCHISTIAKOVA, Davinder GILL, Kodangattil R. SREEKUMAR
  • Patent number: 8846875
    Abstract: Methods, systems and/or kits for the preparation, purification and isolation of oligonucleotide conjugates, comprising conjugation of modified antibodies or proteins with at least one modified oligonucleotide at greater than 80% efficiency to form oligonucleotide conjugates and isolating the oligonucleotide conjugates from the conjugation solution by binding the conjugates to an immobilized binder, wherein the binder may be a metal ion or an antibody.
    Type: Grant
    Filed: February 11, 2011
    Date of Patent: September 30, 2014
    Assignee: Solulink, Inc.
    Inventors: David A. Schwartz, Leopoldo G. Mendoza
  • Patent number: 8846876
    Abstract: Disclosed herein are non-natural amino acids and polypeptides that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The non-natural amino acids, by themselves or as a part of a polypeptide, can include a wide range of possible functionalities, but typical have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid polypeptides that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such polypeptides. Typically, the modified non-natural amino acid polypeptides include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, including therapeutic, diagnostic, and other biotechnology uses.
    Type: Grant
    Filed: June 20, 2012
    Date of Patent: September 30, 2014
    Assignee: Abrx, Inc.
    Inventors: Zhenwei Miao, Junjie Liu, Thea Norman, Russell Driver
  • Patent number: 8834885
    Abstract: The present disclosure relates to immunoglobulins and immunoglobulin conjugates with reduced oligomerization and efficient labeling and compositions, methods of generating such immunoglobulins and immunoglobulin conjugates and methods of using such immunoglobulin conjugates particularly in the treatment and prevention of disease.
    Type: Grant
    Filed: June 4, 2010
    Date of Patent: September 16, 2014
    Assignees: Novartis AG, Massachusetts Institute of Technology
    Inventors: Naresh Chennamsetty, Bernhard Helk, Veysel Kayser, Bernhardt Trout, Vladimir Voynov
  • Publication number: 20140255305
    Abstract: The invention relates to a companion diagnostic antibody-like binding protein based on the humanized monoclonal antibody, DS6, to be used as diagnostic tool for in vivo detection and quantification of the tumor-associated MUC1-sialoglycotope, CA6.
    Type: Application
    Filed: February 5, 2014
    Publication date: September 11, 2014
    Inventors: Jochen Kruip, Sanjiv S. Gambhir, Susanta K. Sarkar, Mathias Gebauer, Christian Lange, Ingo Focken, Richard Kimura, Arutselvan Natarajan, Ohad Ilovich
  • Publication number: 20140243236
    Abstract: Certain disclosed embodiments of the present invention concern the synthesis, derivatization, conjugation to immunoglobulins and signal amplification based on discrete, relatively short polymers having plural reactive functional groups that react with plural molecules of interest. Reactive functional groups, such as hydrazides, may be derivatized with a variety of detectable labels, particularly haptens. The remaining reactive functional groups may be conjugated directly to a specific binding molecule, such as to the oxidized carbohydrate of the Fc region of the antibody. Disclosed conjugates display large signal amplification as compared to those based on molecules derivatized with single haptens, and are useful for assay methods, particularly multiplexed assays.
    Type: Application
    Filed: April 23, 2014
    Publication date: August 28, 2014
    Applicant: Ventana Medical Systems, Inc.
    Inventors: Jerry W. Kosmeder, II, Casey A. Kernag, Donald Johnson, Christopher Bieniarz
  • Publication number: 20140235834
    Abstract: The present invention relates to compounds having the formula (I) and their use in clinical and industrial diagnosis.
    Type: Application
    Filed: April 23, 2014
    Publication date: August 21, 2014
    Applicant: bioMérieux
    Inventor: Xavier Lacoux
  • Publication number: 20140227297
    Abstract: Provided herein is technology relating to theranostic agents and particularly, but not exclusively, to compositions comprising cell-specific theranostic agents and associated methods and systems for using the cell-specific theranostic agents to treat subjects.
    Type: Application
    Filed: February 7, 2014
    Publication date: August 14, 2014
    Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Sascha N. Goonewardena, Bertram Pitt, Hong Zong
  • Publication number: 20140220017
    Abstract: The present invention relates to complexes comprising (i) an immunoglobulin (Ig) binding moiety and (ii) a pharmaceutically active moiety, wherein the Ig binding moiety specifically binds to the constant domain 1 of the heavy chain (CH1) of an Ig molecule and their use for therapy and prophylaxis.
    Type: Application
    Filed: September 24, 2012
    Publication date: August 7, 2014
    Inventors: Roland Kontermann, Felix Unverdorben, Meike Hutt
  • Patent number: 8790649
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to EGFR are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Grant
    Filed: October 28, 2011
    Date of Patent: July 29, 2014
    Assignee: ImmunoGen, Inc.
    Inventors: Julianto Setiady, Peter U. Park, Lingyun Rui, Thomas Chittenden, Gillian Payne
  • Publication number: 20140200333
    Abstract: Dendronic reporters are described which incorporate a high density of luminescent or non-luminescent dyes at periphery sites and a focal point group that is reactive, ionic or a conjugated substance. Such dendronic reporters are capable of sensing analytes, or are otherwise useful in luminescent assays. Additionally, methods of synthesis are described.
    Type: Application
    Filed: August 14, 2012
    Publication date: July 17, 2014
    Applicant: SETA BIOMEDICALS, LLC
    Inventors: Ewald Terpetschnig, Inna G. Yermolenko, Olena M. Obukhova, Anatoliy Tatarets, Leonid D. Patsenker
  • Publication number: 20140199243
    Abstract: Compounds of the following Formula (I): in which A represents either a nitrogen atom, or a ring having 3 to 6 carbon atoms, or an aromatic ring having 5 to 10 members, the ring and the aromatic ring optionally include one or more heteroatoms selected from N, O and S, and W represents a grafting function and X and Y represent chelating functions.
    Type: Application
    Filed: June 18, 2012
    Publication date: July 17, 2014
    Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Loic Charbonniere, Câline Christine, Alexandre Lecointre, Katia Nchmimi Nono
  • Patent number: 8778349
    Abstract: The intrinsically disordered sequences—or “intrinsically disorded sequences” or IDSeq—proteins should be flexible to ensure a controlled interaction between proteins. In the development of the diseases, IDSeq are modified and polymerized. The invention describes the method of preparation of the drugs against cancers, the degenerative diseases and the infectious illness, by the induction of an immune reaction against IDSeq modified in a covalent way (IDSeqC) and polymerized (pIDSeqC), and leading to a new network of protein signaling, named here “misfoldome”, causing the diseases. The invention describes the preparation of vaccines by the use of polymers of IDSeqC. Peptides of the pIDSeqC are prepared in vitro, and introduced into a living organism to induce an immunological response, which eliminates the “misfoldome” and cures the diseases. The method is employed for the preparation of active or passive vaccines.
    Type: Grant
    Filed: October 30, 2008
    Date of Patent: July 15, 2014
    Inventor: Halina Malina
  • Publication number: 20140193926
    Abstract: The invention provides a novel class of reactive fluorescent agents that are based on a pyrene sulfonic acid nucleus. The agents are readily incorporated into conjugates with other species by reacting the reactive group with a group of complementary reactivity on the other species of the conjugate. Also provided are methods of using the compounds of the invention to detect and/or quantify an analyte in a sample. In an exemplary embodiment, the invention provides multi-color assays incorporating the compounds of the invention.
    Type: Application
    Filed: November 14, 2013
    Publication date: July 10, 2014
    Applicant: LIFE TECHNOLOGIES CORPORATION
    Inventors: Richard HAUGLAND, Wai-Yee Leung, Jixiang Liu
  • Publication number: 20140178375
    Abstract: Disclosed herein are recombinant protein scaffolds for use in producing antigen-binding proteins. Related antigen-binding proteins are also provided herein. In addition, nucleic acids encoding such recombinant protein scaffolds and antigen-binding proteins are also described. Vectors and cells useful for expression of the described proteins are also provided, as are methods of use.
    Type: Application
    Filed: March 8, 2012
    Publication date: June 26, 2014
    Applicant: The Trustees of the University pf Pennsylvania
    Inventors: Mark I. Greene, Hongtao Zhang
  • Publication number: 20140170159
    Abstract: Provided herein are modified anti-EGFR antibodies and nucleic acid molecules encoding modified anti-EGFR antibodies. Also provided are methods of treatment and uses using modified anti-EGFR antibodies.
    Type: Application
    Filed: March 8, 2013
    Publication date: June 19, 2014
    Inventors: Ge Wei, Gregory I. Frost, Lei Huang, H. Michael Shepard, Daniel Edward Vaughn
  • Publication number: 20140161870
    Abstract: The present disclosure provides antibodies specific for an epitope present on CD22. The antibodies are useful in various treatment, diagnostic, and monitoring applications, which are also provided.
    Type: Application
    Filed: July 15, 2013
    Publication date: June 12, 2014
    Inventors: David Rabuka, Robert George Edward Holgate, Francis Joseph Carr
  • Publication number: 20140147384
    Abstract: The present invention relates to a radioimmunoconjugate that binds human CD37. Pharmaceutical compositions and uses thereof for the treatment of cancer and in particular B cell malignancies are aspects of the present invention.
    Type: Application
    Filed: December 9, 2013
    Publication date: May 29, 2014
    Applicant: Nordic Nanovector AS
    Inventors: Roy H. Larsen, Jostein Dahle, Øyvind S. Bruland
  • Publication number: 20140141025
    Abstract: The present disclosure provides conjugate structures (e.g., polypeptide conjugates) and hydrazinyl-indole compounds used to produce these conjugates. The disclosure also provides methods of production of such conjugates, as well as methods of using the same.
    Type: Application
    Filed: March 11, 2013
    Publication date: May 22, 2014
    Applicant: REDWOOD BIOSCIENCE, INC.
    Inventors: Romas Alvydas Kudirka, Aaron Edward Albers, Robyn M. Barfield, David Rabuka
  • Publication number: 20140127717
    Abstract: Hydroxamate substituted azaindoline cyanine dyes, conjugates thereof and methods of using the same are provided. The subject cyanine dyes include an azaindoline ring having a hydroxamate substituent. The dyes may further include a reactive group moieties (RGM) and/or a water soluble group. Also provided are conjugates of the subject dyes. Also provided are tandem conjugates including a fluorescent protein capable of energy transfer to the dye. Methods of detecting an analyte in a sample by contacting the sample with a detection reagent are provided. The detection agent may be a dye-conjugate that specifically binds the analyte, or may be a reactive dye which conjugates to the analyte. Also provided are compositions, e.g., kits, etc., incorporating such dyes which facilitate use in such methods.
    Type: Application
    Filed: October 23, 2013
    Publication date: May 8, 2014
    Inventors: Zhenjun Diwu, Haitao Guo, Xing Han, Mirion Schultz, Timothy Dubrovsky
  • Publication number: 20140113315
    Abstract: The invention is directed to a releasable conjugate comprising a biotinylated ligand having a biotin moiety, a ligand moiety (Ligand1) and a biotin-binding molecule (bbm) bound to the biotin moiety of the biotinylated ligand. The ligand moiety of the biotinylated ligand may be separated by a spacer group consisting of polyethylene glycol. Furthermore, the invention relates to a method for cleaving the releasable conjugate by providing biotin or streptavidin and an auxiliary release agent in a sufficient concentration to displace the biotin-binding molecule (bbm) from the biotin moiety of the biotinylated ligand and a method for separation of target cells from a cell sample utilizing the conjugate.
    Type: Application
    Filed: October 2, 2013
    Publication date: April 24, 2014
    Applicant: Miltenyi Biotec GmbH
    Inventors: Jennifer Brieden, Christian Dose
  • Publication number: 20140093450
    Abstract: Described is a pretargeting method, and related kits, for targeted medical imaging and/or therapeutics, wherein use is made of abiotic reactive chemical groups that exhibit bio-orthogonal reactivity towards each other. The invention involves the use of [4+2] inverse electron demand (retro) Diels-Alder chemistry in providing the coupling between a Pre-targeting Probe and an Effector Probe. To this end one of these probes comprises an electron-deficient tetrazine or other suitable diene, and the other an E-cyclooctene which has a flattened structure as a result of the position of at least two exocyclic bonds.
    Type: Application
    Filed: May 7, 2012
    Publication date: April 3, 2014
    Applicant: KONINKLIJKE PHILIPS N.V.
    Inventors: Marc Stefan Robillard, Johan Lub, Raffaella Rossin, Sandra Martina Van Ben Bosch, Ronny Mathieu Versteegen